Altimmune (ALT) Reports First Patient Dosing in Phase 1b Clinical Trial of NasoShield
Go back to Altimmune (ALT) Reports First Patient Dosing in Phase 1b Clinical Trial of NasoShield| iShares Diversified Alternatives Trust (NASDAQ: ALT) | Delayed: 2.93 +0.23 (8.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.70 | 52 Week High | $54.24 | |||
| Open | $2.84 | 52 Week Low | $48.35 | |||
| Day High | $3.05 | P/E | N/A | |||
| Day Low | $2.83 | EPS | $0.00 | |||
| Volume | 5,771,010 | |||||
